Ads
related to: new asthma treatments for adultsdoconsumer.com has been visited by 10K+ users in the past month
assistantsun.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
While developing asthma as an adult is less common than getting it as a kid, asthma rates for people of all ages are rising—one in 12 adults has asthma, according to the latest figures from the ...
It is the first asthma triple-combination therapy; it consists of a fixed-dose combination of three active substances (indacaterol, glycopyrronium bromide and mometasone furoate) in capsules, to be administered using an inhaler. [11] An optional electronic sensor may also be co-packed with the product. [11]
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma. [5] [7] [8] [9] Tezepelumab blocks thymic stromal lymphopoietin (TSLP), [5] an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
The US Food and Drug Administration on Friday approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods.
With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
Ads
related to: new asthma treatments for adultsdoconsumer.com has been visited by 10K+ users in the past month
assistantsun.com has been visited by 10K+ users in the past month